Treace Medical Concepts, Inc. (TMCI)
NASDAQ: TMCI · IEX Real-Time Price · USD
7.88
-0.01 (-0.13%)
At close: Jul 19, 2024, 4:00 PM
7.91
+0.03 (0.38%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Treace Medical Concepts Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TMCI stock have an average target of 10.42, with a low estimate of 6.00 and a high estimate of 25. The average target predicts an increase of 32.23% from the current stock price of 7.88.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for TMCI stock from 7 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $7 → $9 | Hold | Maintains | $7 → $9 | +14.21% | Jul 16, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $5.5 → $8 | Hold | Maintains | $5.5 → $8 | +1.52% | Jul 15, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $16 → $6.5 | Strong Buy → Hold | Downgrades | $16 → $6.5 | -17.51% | May 16, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $15 → $5.5 | Buy → Hold | Downgrades | $15 → $5.5 | -30.20% | May 8, 2024 |
| UBS | UBS | Strong Buy Maintains $17 → $16 | Strong Buy | Maintains | $17 → $16 | +103.05% | May 8, 2024 |
Financial Forecast
Revenue This Year
209.51M
from 187.12M
Increased by 11.97%
Revenue Next Year
234.39M
from 209.51M
Increased by 11.88%
EPS This Year
-0.92
from -0.81
EPS Next Year
-0.86
from -0.92
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 217.9M | 247.0M | 283.9M | 326.6M | 375.6M |
| Avg | 209.5M | 234.4M | 261.4M | 317.2M | 364.9M |
| Low | 200.0M | 216.1M | 236.6M | 304.8M | 350.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.4% | 17.9% | 21.1% | 24.9% | 18.4% |
| Avg | 12.0% | 11.9% | 11.5% | 21.3% | 15.0% |
| Low | 6.9% | 3.1% | 0.9% | 16.6% | 10.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.86 | -0.78 | -0.72 | -0.49 | -0.26 |
| Avg | -0.92 | -0.86 | -0.79 | -0.48 | -0.26 |
| Low | -0.94 | -1.01 | -1.02 | -0.46 | -0.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.